BIOMARKERS FOR THERAPY, BASED ON HEDGEHOG INHIBITOR Russian patent published in 2016 - IPC G01N33/574 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and method of analyzing of biological sample from patient suffering from medulloblastoma, including determination of expression level of five biomarkers GLI-1, OTX-2, SHROOM2, PDLIM3 and SPHK1 in biological sample, taken from patient, where increased expression level of biomarkers GLI-1, SHROOM2, PDLIM3 and SPHK1 and low expression level of biomarker OTX-2, compared with reference, is diagnostic indicator of patient with high probability of response to [6-(cis-2,6-dimethylmorpholine-4-yl)-pyridine-3-yl]-amide of methyl-4′-trifluoromethoxyphenyl-3-carboxylic acid. Group of inventions also concerns method of sampling patient suffering from medulloblastoma, for treating with Hedgehog signalling pathway inhibitor; kit for determination whether medulloblastoma tumor is sensitive to treatment with Hedgehog signalling pathway inhibitor; method of medulloblastoma treatment in patient, requiring it.

EFFECT: group of inventions provides predicting response of patients with medulloblastoma to treatment using Hedgehog signalling pathway inhibitor.

8 cl, 5 ex, 3 tbl